Publication number: 20120329830
Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein ring A, B1, B2, B3, L, R1, R4, R5 and m of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
Type:
Application
Filed:
November 19, 2010
Publication date:
December 27, 2012
Applicant:
Amgen Inc.
Inventors:
Yuan Cheng, Timothy Powers, Kate Ashton, James Brown, Scott Harried, Stephen A. Hitchcock, Ted Judd, Patricia Lopez, Thomas Nixey, Nick A. Paras, Steve F. Poon, David J. St. Jean, JR., Qiufen Xue, Wenge Zhong
Publication number: 20110251186
Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, R2, R7, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
Type:
Application
Filed:
March 14, 2011
Publication date:
October 13, 2011
Applicant:
Amgen Inc.
Inventors:
Jian J. CHEN, Wenge ZHONG, Bryant YANG, Wenyuan QIAN, Patricia LOPEZ, Ryan WHITE, Matthew WEISS, Ted JUDD, Timothy POWERS, Yuan CHENG, Thomas DINEEN, Oleg EPSTEIN, Jonathan LOW, Isaac MARX, Ana Elena MINATTI, Michele POTASHMAN, Nick A. PARAS
Publication number: 20110251190
Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and other related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, R2, R7, X and Y of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
Type:
Application
Filed:
March 14, 2011
Publication date:
October 13, 2011
Applicant:
Amgen Inc.
Inventors:
Yuan CHENG, Ryan White, Albert Amegadzie, James Brown, Alan C. Cheng, Erin F. Dimauro, Thomas Dineen, Oleg Epstein, Vijay Keshav Gore, Jason Brooks Human, Ted Judd, Charles Kreiman, Qingyian Liu, Patricia Lopez, Vu Van Ma, Isaac Marx, Ana Minatti, Hanh Nho Nguyen, Nick A. Paras, Vinod F. Patel, Wenyuan Qian, Matthew Weiss, Qiufen Xue, Xiao Mei Zheng, Wenge Zhong
Publication number: 20070054916
Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A1, A2, A3, B, R1, R2, R3 and R4 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.
Type:
Application
Filed:
September 30, 2005
Publication date:
March 8, 2007
Inventors:
Vinod Patel, Joseph Kim, Stephanie Geuns-Meyer, Stuart Chaffee, Victor Cee, Brian Hodous, Steven Bellon, Jean-Christophe Harmange, Philip Olivieri, Maya Thaman, Erin DiMauro, John Buchanan, David McGowan, Brian Albrecht, Holly Deak, Jean Bemis, Ryan White, Matthew Martin, Gregory Habgood, Paul Tempest, Craig Masse, William Buckner, Bradley Herberich, Russell Graceffa, Dawei Zhang, Shimin Xu, Kelvin Sham, Robert Rzasa, James Falsey, Partha Chakrabarti, Guo-Qiang Cao, Susan Tomlinson, Liping Pettus, Adrian Smith, Nick Paras, Gang Liu, Frenel DeMorin, Andrew Tasker, Anthony Reed